CClinicalTrials.gg
CompletedNCT04041869Updated May 15, 2023Results posted

Residential MapTrek- Increasing Physical Activity Among Older Adults in a Residential-Living

An interventional study of MapTrek in Sedentary Behavior, sponsored by University of Iowa. Completed at 1 site in United States. Open to participants aged 25 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by University of Iowa · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
25 Years to 100 Years
Sex
All
01

Study summary

Older adults are a growing population, with projections to reach 83.7 million by 2050. Furthermore, older adults are the most sedentary and least physically active adult population. It is estimated that nearly 90% of older adults 65 years of age or older do not meet the recommended levels of physical activity. Evidence suggests great health benefits can be achieved for older adults who are the most sedentary, and that replacing sitting with even light intensity walking can be beneficial.

The overarching goal of the project is to develop an inexpensive and scalable tool to increase volume of physical activity in our target population, older adults living in a residential facility. MapTrek is a web-based application that allows participants to take a virtual walk in interesting locations around the world while tracking their progress against the progress of other older adults living in a retirement community. Steps are counted using a commercially available accelerometer (e.g., Fitbit), and participants see their progress overlaid on Google Maps.

Read the detailed description

All participants will be provided with a Fitbit activity monitor and instructed to wear it 24 hours/day (except for bathing/swimming time) on their wrist for 12 weeks. Participants will participate in four team-based walking races, each two weeks long. Participants will view their team progress on TV monitors placed in various locations at the Oaknoll facility. The Oaknoll leadership has given the research team approval to do this at their facility. The monitors will present aggregated team data and will not report any individual data that could link back to the individual participant.

At the end of the 8 week active intervention, research team members will meet with participants at Oaknoll to administer an exit/process evaluation survey. The exit survey will ask about psychosocial predictors of physical activity as well as participants thoughts and opinions of the MapTrek game. This survey should take approximate 10-15 minutes to complete. The participants will then be asked to wear the Fitbit for four more weeks without playing MapTrek, which will act as a control condition since this is a single-arm study.

The specific aims of the study are:

  1. To determine the efficacy of MapTrek for improving physical activity levels of older adults living in a residential facility from baseline to 8 weeks.
  2. To determine the efficacy of MapTrek for improving psychosocial outcomes(e.g., self-efficacy, social support, outcome expectations, social isolation) among older adults living in a residential facility from baseline to 8 weeks.
02

Conditions studied

  • Sedentary Behavior

Keywords

  • Older adults
  • Walking
  • Fitbit
03

In context

Lead sponsor

University of Iowa is the lead sponsor of 276 studies on the registry; 35 are open to participants now.

Of its 44 completed or terminated interventional studies of FDA-regulated products, 39 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • To be eligible, participants much be between 25 and 100 years of age, physically able to walk without limitations

Exclusion criteria

Exclusion Criteria:

  • Patients with cognitive or physical limitations that prohibit walking and visual or cognitive impairments causing inability to read.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    MapTrek

    Behavioral: MapTrek

Interventions

  • BehavioralMapTrek

    Participants will receive a Fitbit activity monitor and access to the MapTrek game which will be visible on monitors set up in the residential facility.

06

What researchers measure

Primary outcomes

  1. Physical Activity

    Daily steps

    Time frame: 8 weeks

Secondary outcomes

  1. Self-efficacy

    Self-efficacy was measured with the Self-Efficacy for Exercise scale, a 13-item questionnaire designed to assess participants' self-efficacy related to their ability to continue exercising in the face of barriers.

    Time frame: 8 weeks

  2. Social Support

    Social support for physical activity was measured with a modified version of the Social Support and Exercise Survey. The Social Support and Exercise Survey is a 12-item (originally 13 item) questionnaire that assesses the level of support from family and friends that participants have in making health behavior changes (exercise)

    Time frame: 8 weeks

  3. Outcome Expectations

    Outcome expectations were measured with the Outcome Expectations for Exercise Scale. The Outcome Expectations for Exercise is a valid and reliable 9-item scale that assesses the participant's outcome expectations and benefits associated with exercise.

    Time frame: 8 weeks

  4. Social Isolation

    Social isolation was measured with a modified version of the Friendship Scale. The Friendship Scale is a 5-item (originally 6-item) scale that assesses 6 dimensions contributing to social isolation

    Time frame: 8 weeks

07

Results

Posted Aug 11, 2022

Participant flow

Participants were recruited from June 17, 2019 to June 27, 2019, by word of mouth and through advertisements posted on digital monitors located throughout the retirement community.

Participant flow — Overall Study
MilestoneMapTrek
Started68
Completed54
Not completed14

Outcome measures

PrimaryPhysical Activity

Daily steps

Time frame:
8 weeks
Reported as:
Mean · Steps/day
Physical Activity
Steps/dayMapTrek
Physical Activity6681 (5840 to 7522)
Statistical analysis
  • MapTrek · Mixed Models Analysis · p = <0.01 · Mean difference (final values): .01
SecondarySelf-efficacy

Self-efficacy was measured with the Self-Efficacy for Exercise scale, a 13-item questionnaire designed to assess participants' self-efficacy related to their ability to continue exercising in the face of barriers.

Time frame:
8 weeks
Reported as:
Mean · cumulative score (0-90); higher=better
Self-efficacy
cumulative score (0-90); higher=betterMapTrek
Self-efficacy67.4 ± 15.2
SecondarySocial Support

Social support for physical activity was measured with a modified version of the Social Support and Exercise Survey. The Social Support and Exercise Survey is a 12-item (originally 13 item) questionnaire that assesses the level of support from family and friends that participants have in making health behavior changes (exercise)

Time frame:
8 weeks
Reported as:
Mean · mean score (0-4 range); higher=better
Social Support
mean score (0-4 range); higher=betterMapTrek
Social Support2.2 ± 0.8
SecondaryOutcome Expectations

Outcome expectations were measured with the Outcome Expectations for Exercise Scale. The Outcome Expectations for Exercise is a valid and reliable 9-item scale that assesses the participant's outcome expectations and benefits associated with exercise.

Time frame:
8 weeks
Reported as:
Mean · mean score (1-5 range) lower=better
Outcome Expectations
mean score (1-5 range) lower=betterMapTrek
Outcome Expectations4.4 ± 0.6
SecondarySocial Isolation

Social isolation was measured with a modified version of the Friendship Scale. The Friendship Scale is a 5-item (originally 6-item) scale that assesses 6 dimensions contributing to social isolation

Time frame:
8 weeks
Reported as:
Mean · cumulative score (4-20) higher=better
Social Isolation
cumulative score (4-20) higher=betterMapTrek
Social Isolation17.6 ± 2.7

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MapTrek0/54 (0%)0/54 (0%)0/54 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)MapTrek
<=18 years0
Between 18 and 65 years0
>=65 years54
Age, Continuous
Age, Continuous(years)MapTrek
Mean81.2 (68 to 92)
Sex: Female, Male
Sex: Female, Male(Participants)MapTrek
Female44
Male10
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MapTrek
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White53
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)MapTrek
United States54
Physical Activity
Physical Activity(Steps/day)MapTrek
Mean5438 (4620 to 6256)
Self-efficacy
Self-efficacy(units on a scale)MapTrek
Mean73.2 ± 14.1
Social Support
Social Support(units on a scale)MapTrek
Mean2.2 ± 0.7

2 further baseline measures are reported on the registry.

08

Study locations

1 site
  • University of Iowa
    Iowa City, Iowa 52242, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Aug 28, 2019
  • Informed consent form · Sep 10, 2019

Documents are hosted by the registry — open the source record to download them.

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04041869
Lead sponsor
University of Iowa
Collaborators
National Institutes of Health (NIH), National Center for Advancing Translational Sciences (NCATS)
Responsible party
Lucas Carr (Associate Professor, Department of Health & Human Physiology, University of Iowa) — Principal investigator
First posted
Aug 1, 2019
Start date
Jun 17, 2019
Primary completion
Sep 22, 2019
Completion
Sep 22, 2019
Results posted
Aug 11, 2022
Last update
May 15, 2023

Study contacts

Lucas Carr, PhD
principal investigator · University of Iowa

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion